Up to date clinical tests for predicting cancer chemotherapy response are not available and individual markers have shown little predictive value. We hypothesized that gene expression patterns attributable to chemotherapy-resistant cells can predict response and cancer prognosis. We contrasted the expression profiles of 13 different human tumor cell lines of gastric (EPG85-257), pancreatic (EPP85-181), colon (HT29) and breast (MCF7 and MDA-MB-231) origin and their counterparts resistant to the topoisomerase inhibitors daunorubicin, doxorubicin or mitoxantrone. We interrogated cDNA arrays with 43 000 cDNA clones (B30 000 unique genes) to study the expression pattern of these cell lines. We divided gene expression profiles into two sets: we compared the expression patterns of the daunorubicin/doxorubicin-resistant cell lines and the mitoxantrone-resistant cell lines independently to the parental cell lines. For identifying predictive genes, the Prediction Analysis for Mircorarrays algorithm was used. The analysis revealed 79 genes best correlated with doxorubicin resistance and 70 genes with mitoxantrone resistance. In an independent classification experiment, we applied our model of resistance for predicting the sensitivity of 44 previously characterized breast cancer samples. The patient group characterized by the gene expression profile similar to those of doxorubicin-sensitive cell lines exhibited longer survival (49.7726.1 months, n ¼ 21, P ¼ 0.034) than
Introduction
The ability of cancer cells to acquire simultaneous resistance to different drugs is a significant obstacle to successful chemotherapy and is commonly designated as multidrug resistance (MDR). MDR may be achieved by a variety of mechanisms including the overexpression of ATP-dependent membrane transporters like P-glycoprotein (P-gp, MDR1, ABCB1), the multidrug resistance proteins MRP1 and MRP2 (ABCC1, ABCC2) or the mitoxantrone resistance protein/breast cancer resistance protein (MXR, BCRP, ABCG2) (Gottesman et al., 2002) . P-gp is involved particularly in drug resistance of colon, kidney, adrenocortical and hepatocellular cancers as well as of acute myelogenic leukemia (AML) (Goldstein et al., 1989) . In vivo imaging studies of breast carcinomas using the P-gp substrate 99m Tc-sestamibi, developed for monitoring cardiac function, showed that transporter activity is increased in breast tumors and demonstrated its potential as predictive marker for tumor response towards treatment with anthracyclines and vinca alkaloids (Alonso et al., 2002; Sciuto et al., 2002) . The MRP1 gene is overexpressed in leukemias, esophageal carcinoma and non-small-cell lung cancers among others (Nooter et al., 1995) . Additionally, drug resistance is mediated by defects in intrinsic safeguard mechanisms capable of eliminating cells by apoptosis. The loss of programmed cell death induced by antitumor drugs can be achieved via disruption of regulators of DNA damage signaling, such as p53 and bcl-2 (Fisher et al., 1993; Lowe et al., 1994) .
Systemic chemotherapies are widely used for the treatment of breast cancer. Efficient response to preoperative treatment has prognostic value because it is correlated with increased survival. The estrogen receptor status is predictive for response to hormonal treatment (Kuerer et al., 1999; Chollet et al., 2002) . Despite its central role in mammary biology and carcinogenesis, the estrogen and progesterone receptor status does not effectively predict the sensitivity against cytotoxic drugs. Doxorubicin is widely used in the treatment of breast cancer, it is involved in four of the six protocols defined by the American Cancer Society (protocols named CAF, AC, AC þ and A-CMF). Mitoxantron is used in monotherapy for treating metastatic breast cancer. The clinical decision for the application of anthracyclines, taxane-derivatives or other combinations of drugs is made regardless whether the patient's tumor is likely to respond to it or not. Predictions of therapy sensitivity based on single marker genes such as P-gp or MRP1 have often been inconclusive. The closest correlation between P-gp expression and drug resistance has been reported for AML. Nevertheless, P-gp overexpression does not correctly predict relapse cases (Gottesman et al., 2002) .
High-density microarrays can help to identify relevant genes involved in tumor pathogenesis and to classify different tumor entities and even tumor subtypes. For example, Sorlie and others have comprehensively examined expression profiling data to confirm the universality of distinguishing basal-and luminal-like breast cancer subtypes and established a correlation to clinical outcome (Sorlie et al., 2003; Sotiriou et al., 2003) . Moreover, van't Veer et al. (2003) demonstrated that breast cancer prognosis can be deduced from the gene expression profile of primary tumors. Chang et al. (2003) demonstrated that gene expression profiles of primary breast cancer could predict the response to docetaxel. Thus, the molecular profiles may allow the development of microarray-based assays for drug sensitivity and help to reduce unnecessary treatment of women with breast cancer.
The results of microarray analysis aiming at elucidating gene patterns associated with cytotoxic drug resistance may be obscured by the presence of various cell types in heterogeneous cancer specimens. Therefore, we firstly generated gene expression patterns of 13 welldefined chemotherapy-resistant and -sensitive cancer cell lines in order to identify discriminatory genes associated with drug resistance in four different types of solid tumors. Secondly we contrasted the cell linederived gene expression profiles with those of a set of precharacterized mammary cancer patients (Sorlie et al., 2003) to use molecular signatures for predicting the patient response to chemotherapy in conjunction with prognosis.
Results

Identification of discriminatory genes
To identify discriminatory genes for predicting sensitivity to doxorubicin and mitoxantrone, we contrasted gene expression profiles of closely related drug-resistant and -sensitive cancer cell lines. Prior to microarray analysis, we verified drug-related reactive pattern of eight sensitive and drug-resistant cell lines by XTT assay as described in Materials and methods. The proliferation of HT29 colon cancer cells at increasing drug concentrations is depicted in Figure 1 as a representative example. We confirmed previously published data (Lage et al., 2000; Lage and Dietel, 2002) indicating that the resistance pattern is a robust feature upon prolonged cultivation. Table 1 summarizes the characteristics of the entire set of multidrug-resistant human cancer cell lines used in this study. For gene expression profiling, RNA was prepared from nontreated parental cells and from resistant derivatives cultured in the presence of daunorubicin and mitoxantrone at a drug concentration which eliminated the majority of sensitive cells (Figure 1,  arrows) .
We divided gene expression profiles obtained for all cell lines into two sets: we compared the expression patterns of the daunorubicin/doxorubicin-resistant cell lines and the mitoxantrone-resistant cell lines independently to the parental cell lines. We selected genes that were present in at least three RNA samples within a sample set of four. In all, 37 771 sequences remained in the doxorubicin resistance set and 32 943 in the mitoxantrone resistance set. The complete filtered and normalized data set is shown as supplementary information (see Supplementary Table 1) .
To select discriminatory genes, we compared the expression profiles of the resistant and parental cell Prediction of drug sensitivity using cDNA array signatures B Györffy et al lines. During the Prediction Analysis for Microarrays (PAM) training analysis, we applied batch adjustment to filter out the differences between the four different cell types. The prediction analysis of microarrays was performed with the genes differentially expressed independent of tissue origin at thresholds 3. Centroid plots for the top 30 genes associated with doxorubicin and mitoxantrone resistance are shown in Figure 2 . We have listed the resistance-associated genes in Supplementary Tables 2 and 3 . The mRNA levels of these genes showed a 15-fold decrease to 20-fold increase in the resistant cells compared to the sensitive parental cell lines. Furthermore, we were able to confirm the previously reported altered expression of P-gp, MRP and BCRP in the investigated cell lines Sinha et al., 1999) .
To classify discriminatory genes, we have performed hierarchical clustering on the genes associated with drug resistance (Figure 3 ). The clustering dendrograms show the 79 genes associated with doxorubicin resistance and the 70 genes associated with mitoxantrone resistance. Three different cDNA clones representing the gene encoding the ABCB1 transporter consistently cluster in the doxorubicin-resistant group.
TaqMan analysis of the ABCB1 gene using two independent probes verified these results: the ABCB1 is upregulated in the EPP181RDB, EPG257RDB and MCF7RADR, but not in the HT29RDB cell line compared to the expression in the parental cell lines (Figure 4 ). The upregulation of caspase I in the doxorubicin-resistant group (fold change: 5.2, Po0.001), and the downregulation of TOP2A in the novantron-resistant group (fold change: À4.3, Po0.001) was verified by quantitative RT-PCR.
Prediction testing on breast-cancer specimens
We used the gene expression profiles derived from doxorubicin-resistant cell lines for an independent classification of clinical specimens. As a test set for this classification, we used 44 breast cancer expression profiles described by Sorlie et al. (2003) . The data were obtained from the Stanford Microarray Database (http://genome-www5.stanford.edu/). The tumor specimens were selected, because the patients had received doxorubicin monotherapy and the survival parameters were reported. Moreover, gene expression profiling of breast cancers was performed on the same technical platform. Recently, a considerable divergence across different platforms has been reported (Tan et al., 2003) . We dismissed one patient, who died within 3 months after surgery probably due to postoperative complications. Although Sorlie et al. used the same cDNA microarray facility, the proportion of common cDNA clones represented on their arrays was only 16% compared to our study, and most of the selected top sequences were not present. For this reason, we performed our prediction independently of the previously selected gene list: first, we constructed a matched gene list between our arrays and the arrays used by Sorlie et al. This matched gene list contained 5923 sequences (Supplementary Table 4 ). Gene sets obtained by comparing the parental and resistant cell lines were used as a training set for the prediction of the clinical samples (test set). For the prediction, we applied PAM to classify the patients rather than to build a new predictor based on this limited gene set. Therefore, we set the threshold to 1, having about 1500 genes analysed for the classification. Based on the corresponding expression profiles, we then grouped the patients' tumors as predicted to be doxorubicin resistant or sensitive. Afterwards, we performed a survival analysis ( Figure 5 and Supplementary Table 5 ). The patients whose tumors were classified as being resistant had a mean survival time of 32.9718.7 months (n ¼ 23), while in the group of patients whose tumors were classified as being sensitive, the mean survival was 49.7726.1 months (n ¼ 21, resistant vs sensitive: P ¼ 0.034). Only three patient tumors (7% of total) were classified as sensitive, while the patients died earlier than 2 years after tumor resection. We failed to use the training set of genes related to mitoxantrone resistance for a similar prediction, this was due to the lack of reported clinical data. Gottesman et al., 2002) and supports the notion that MDR is highly complex. The generally accepted major candidates for drug resistance are the MDR proteins, which actively expel cytotoxic drugs from the cell, maintaining the drug level below a cell killing threshold (Bodo et al., 2003 Prediction of drug sensitivity using cDNA array signatures B Györffy et al have grouped the already identified genes involved in resistance against doxorubicin and mitoxantrone into functional classes comprising elements involved in signaling, cell migration, transport, apoptosis and detoxification (Table 2) . We retrieved additionally a high proportion of differentially expressed sequences without known function. In all, 49% percent of sequences associated with doxorubicin resistance and 44% of sequences related to mitoxantrone resistance were ESTs, which might represent novel genes associated with cytostatic multidrug resistance. Our experiment utilized expression patterns of precharacterized and well-defined resistant and sensitive cell line pairs for therapy response prediction. Up to date clinical and pathological markers poorly predict response to chemotherapy probably due to the multifactorial nature of cancer multidrug resistance. The use of several different cell lines for the construction of a prediction model enables the application on different tissues. So far, gene expression profiling has already been used for identifying factors related to the resistance toward cytostatic drugs in cell lines (Kudoh et al., 2000; Staunton et al., 2001 ) and human cancer xenografts (Zembutsu et al., 2002) . Studies based on cancer specimens have concentrated on the classification of tumor subtypes and patient prognosis rather than on drug response (Sorlie et al., 2003; van't Veer et al., 2003) . Few studies have correlated expression profiles of breast tumors to their sensitivity to anticancer drugs (Chang et al., 2003) . A novel study identified a predictive gene list for the sequential T/FAC (paclitaxel and fluorouracil þ doxorubicin þ cyclophosphamide) protocol in breast cancer (Ayers et al., 2004) .
By hierarchical clustering, Sorlie et al. identified different subgroups of breast carcinomas. They found that patients in the newly identified luminal A cluster had better prognosis than patients in the luminal B and other clusters. We found that our distribution of resistant and sensitive predictions shows high representation of sensitive samples in the luminal A cluster and low representation in the luminal B cluster (Figure 6 ). Our result suggests that higher drug sensitivity may be responsible for better patient survival in the luminal A cluster. This is also supported by the altered expression in the genes that have previously been associated with multidrug resistance (for example MDR1, CYP27A1, EGFR, CISH, TOP2A). Furthermore, our prediction model seems to be applicable for the unclassified samples from Sorlie et al., with respect to survival, but not histomorphology.
While doxorubicin was used to induce the resistance in our investigated breast cell line, the selective agent for the other cell lines (EPG85-257, EPP85-181 and HT29) was daunorubicin. Although these are similar anthracycline drugs acting via topoisomerase inhibition, this has to be taken in consideration when future prediction analyses are performed.
A recent microarray study correlated in vitro response to chemotherapy in four cell lines to response in breast tumors (Troester et al., 2004) . The common discriminatory genes in their study do not overlap with our results. The reason for this is probably due to the study design: while Troester et al. have investigated treatment response after 12-, 24-and 36-h drug administration, we have focused on the pre-existing characteristics of the resistant cell lines. Although short-and long-term drug administration may have different effect on gene expression, both sets of responsive genes could be used in predictive tests. A combined study with all selected genes could give more insight into the dynamics and course of gene expression changes during treatment.
Doxorubicin resistance was investigated using microarrays in two recent studies (Suganuma et al., 2003; Kang et al., 2004) . Suganuma et al. investigated genes related to chemoresistance towards cisplatin, doxorubicin, mitomycin C and 5-fluorouracil in gastric cancer. Prediction of drug sensitivity using cDNA array signatures B Györffy et al Zinc-finger protein, and has been shown to inhibit NF-k B activation as well as TNF-mediated apoptosis, knockout studies of a similar gene in mice suggested that this gene is critical for limiting inflammation by terminating TNF-induced NF-kB responses ESTs are excluded.
Prediction of drug sensitivity using cDNA array signatures B Györffy et al However, the 20 specimens analysed in this study exhibited drug resistance, and none of them was sensitive to drug treatment. Therefore, a list of candidate genes specifically associated with doxorubicin resistance could not be established. In the second study, performed on a different microarray platform, Kang et al. identified gene expression patterns related to resistance against 5-fluorouracil, cisplatin and doxorubicin in 14 human gastric cancer cells. We have compared the published set of 250 differentially regulated genes with our prediction profiles, but we have not detected an overlap. These results are in line with the findings of a recent study demonstrating that different gene signatures can achieve similar prediction success for the same classification problem (Ein-Dor et al., 2005) . Moreover, alternative microarray platforms may yield different results (Tan et al., 2003) . We designed our study to identify patterns of gene expression that could be used in a predictive test for the investigated chemotherapy agents. Our study shows that DNA microarray technology can effectively be used for predicting the response to chemotherapy and indirectly the patient prognosis. The results of the resistance pattern derived from our cell lines can help in the development of customized DNA arrays for doxorubicin and mitoxantrone resistance. To define ultimately the complete molecular portrait of drug sensitivity and resistance, our results should be validated in a study with a large independent cohort of patients.
Materials and methods
Cell lines
The human gastric carcinoma cell line EPG85-257P and its drug-resistant derivatives were established in our laboratory and described in detail previously (Dietel et al., 1990; Lage et al., 2000) . Likewise, the human pancreatic carcinoma cell line EPP85-181P and its drug-resistant sublines were established in the same way (Lage and Dietel, 2002) . In accordance drug-resistant cell variants of the human colon carcinoma cell line HT29 with (Chen et al., 1987) , and the breast cancer cell lines MCF7 (Soule et al., 1973) and MDA-MB-231 (Cailleau et al., 1974) were also established in our laboratory. Cell culture was performed as described (Lage et al., 2000; Lage and Dietel, 2002) . The selection agents and conditions are summarized in Table 1 . Daunorubicin and doxorubicin were obtained from Farmitalia Carlo Erba (Freiburg, Germany); mitoxantrone was purchased from Lederle (Wolfratshausen, Germany).
Cell proliferation assay
We re-examined the drug resistance of each resistant derivative relative to the sensitive parental line by culturing the cells in the presence of drugs ranging from 0.0001 to 100 mg/ml for a period of 5 days. Proliferation was assessed using an XTT Cell Proliferation kit following the manufacturer's instructions (Roche, Germany) (Roehm et al., 1991) . To determine the IC 50 values, the formazan release of control cells without drug was set to 100%. Linear regression was plotted for the linear region of the growth curves obtained in at least three independent experiments for each cell line.
mRNA preparation
RNA isolation was performed 24 h after cell seeding from all cell lines. The log-phase growing cells were lysed with TRIzol s and RNA was isolated following the manufacturer's protocol. Poly(A) RNA was prepared using the Fast Track 2.0 mRNA isolation kit (Invitrogen Life Technologies). RNA quality from each sample was assessed by visualization of the 28S/18S ribosomal RNA ratio using an Agilent 2100 Bioanalyser.
Array hybridization
We interrogated cDNA arrays with 43 009 cDNA clones, representing approximately 30 000 unique genes for studying the expression patterns of the 13 cell lines. Microarrays were hybridized as described previously (Alizadeh et al., 2000; Sorlie et al., 2003) . Briefly, 3 mg of mRNA was reverse transcribed in the presence of Cyt5-dUTP. In all, 50 mg of Universal Human RNA (Stratagene) was Cyt3 labeled as a reference. Hybridization was carried out at 651C for 12-16 h. Slides were washed for 3 min in 2 Â SSC, 0.075% SDS at 501C, then for 3 min in 1 Â SSC and finally for 2 min in 0.1 Â SSC. Glass slides were promptly centrifugated at 600 r.p.m. for 10 min and the fluorescent images of hybridized microarrays were obtained using a GenePix 4000 microarray scanner (Axon Instruments). The images of all scanned slides were inspected for artifacts, and aberrant spots and slide regions were flagged for exclusion from analyses.
Statistical analysis
Log 2 (Cy5/Cy3) was retrieved for each spot prior to further analysis. Cy5/Cy3 is the normalized ratio of the backgroundcorrected intensities. To reduce the effect of nonspecific fluorescence, we filtered spots as follows: the mean background for the red and green signals of each array was determined by calculating the average of the mean background of the corresponding color intensities of all spots in the array. The net signal was determined by subtraction of this local background from the average intensity of each spot. Then, the signals were normalized by applying a single multiplicative Prediction of drug sensitivity using cDNA array signatures B Györffy et al factor to all intensities measured for the red dye (Cy5). The normalization factor was chosen in order to achieve the mean log(Cy5/Cy3) for the spots of 0.0, this effectively defining the signal-intensity-weighted 'average' spot on each array to have a Cy5/Cy3 ratio of 1.0. For identifying predictive genes, the PAM (v.1.12) package was used as described by Tusher et al. (2001) . PAM uses soft thresholding to produce a shrunken centroid, which allows the selection of genes with high predictive potential. Hierarchical clustering was performed using the Genesis software (Sturn et al., 2002) . Univariate Kaplan-Meier analysis was performed by using Winstat for Excel (R Fitch Software, Staufen, Germany). All hybridization data are stored in the Stanford Microarray Database and can be accessed at http://genome-www5. stanford.edu/. The combined data sets for prediction analysis are made available as supplementary information on the journal web site.
Validation
We have performed TaqMan verification for the ABCB1 gene to validate the results obtained on cDNA arrays using an Applied Biosystems 7900HT Sequence Detection System. The results of two independent ABCB1 TaqMan probes (Hs00184491 and Hs00184500) were normalized to GAPDH (probe Hs99999905) expression. The measurements were performed as described in the 7900HT products user guide (http://www.appliedbiosystems.com, CA, USA 0 -ctcttgacctgtcccctctg-3 0 ) and for G6PDH, a 113 bp amplicon was produced, detected by gene-specific fluorescein and LCRed640-labeled hybridization probes (caspase I and topoisomerase II alpha primer syntheses: BioTeZ, Berlin, Germany; probe syntheses: TIB MOLBIOL, Berlin, Germany; G6PDH primer and probe syntheses: Roche Diagnostics). The calibrator cDNA derived from EPP181 cells and was employed in serial dilutions simultaneously in each run.
